글로벌 항균 펩타이드 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

미국 질병통제예방센터에 따르면 2013년에 200만 건 이상의 건강 관련 문제가 보고되었고, 23,000명이 약물 내성 박테리아로 인해 사망했습니다. 2012년에 미국에서 450,000건 이상의 다중 약물 내성 결핵 신규 사례가 보고되었습니다. 전 세계적으로 약물 내성 환자가 증가함에 따라 일반적인 감염성 질환 에 맞서기 위한 새로운 항생제 개발이 필요합니다 . 옥시토신, 사이클로스포린, 연어 칼시토닌, 인테그릴린, 졸라덱스와 같은 펩타이드는 잘 알려져 있으며 전 세계적으로 펩타이드 요법 사업을 새로운 방향으로 이끌고 있습니다.

Data Bridge Market Research는 2021년에 50억 달러였던 항균 펩타이드 시장이 2029년까지 78억 5천만 달러로 급증할 것으로 분석했으며, 2022년부터 2029년까지 예측 기간 동안 5.80%의 CAGR을 보일 것으로 예상합니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 시장 세그먼트, 지리적 범위, 시장 참여자, 시장 시나리오와 같은 시장 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석, 규제 프레임워크가 포함되어 있습니다.

보고 범위 및 시장 세분화

Market Definition

Antimicrobial peptides are compounds that are part of the host defence mechanism in both prokaryotic and eukaryotic cells, defending them from dangerous infective threats such as bacteria, viruses, and even fungi. Antimicrobial peptides is very dependent on their composition, and they are used to target cytoplasmic membranes, cell walls, DNA, and proteins.

Antimicrobial Peptides Market Dynamics

Drivers

• Technological advancements

With a growing pool of scientists and talented technocrats interested in the arena for innovative therapeutics containing antimicrobial peptides for rare diseases, institutional research is substantially invested. Antimicrobial peptides, for example, can be created for a variety of purposes ranging from extending the shelf life of food packaging to delivering bioactive substances in therapeutic sectors driving the market.

• Rise in infectious diseases

The rising frequency of infectious diseases and the rising demand for effective and safe medicines are driving the expansion of the antimicrobial peptides market. Furthermore, the use of AMPs in a variety of applications is likely to fuel market expansion throughout the forecast period.

• Usage of antimicrobial peptides

Antimicrobial peptides are gaining popularity as therapeutic agents for a variety of ailments, including skin infections. Antimicrobial peptides are a promising newcomer in the field of immune modulation and antifungal drugs. Anti-microbial peptides aid in the improvement of anti-inflammatory cell responses and have the ability to breakdown malignant cell membranes, making them a possible cancer treatment medicine. Anti-microbial peptides market is expected to develop in the near future due to rising demand for cancer, HIV, and diabetes therapy.

Opportunities

When compared to the hazards that exist, the prospects for producing antimicrobial peptides are greater. Antimicrobial peptides' use in the treatment of Hepatitis C, pneumonia, bacterial infections, HIV AIDS, and cancer is likely to increase public acceptability of the treatments. Due to increased awareness to medications and therapies incorporating antimicrobial peptides, the global market for antimicrobial peptides is expected to rise significantly. Chronic disorders where antibiotic resistance is ineffective give a more attractive opportunity for antimicrobial peptides manufacturers.

Restraints/Challenges

Furthermore, antimicrobial peptides are now undergoing clinical trials, and the stability and half-life of antimicrobial peptides in vivo are unknown. These issues are limiting the global growth of the antimicrobial peptides market.

This antimicrobial peptides market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the antimicrobial peptides market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Covid-19 impact on Antimicrobial Peptides Market

In all countries, the COVID-19 pandemic poses a major public health threat. The effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on future global health, especially the pandemic's possible impact on the emergence and spread of worldwide antibiotic resistance, are still being explored (AMR). COVID-19 patients who are critically ill may develop significant problems that predispose them to infection with nosocomial bacterial and/or fungal pathogens, necessitating the use of antibiotics. Antibiotics, on the other hand, may be used incorrectly in milder cases of COVID-19 infection. Concerns about increased biocide use, antimicrobial stewardship/infection control, antimicrobial resistance (AMR) awareness, the need for diagnostics (including rapid and point-of-care diagnostics), and the efficacy of vaccination could all play a role in determining the impact of the COVID-19 pandemic.

Global Antimicrobial Peptides Market Scope

The antimicrobial peptides market is segmented on the basis of product type, ailments, distribution channel, route of administration, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Plant Antimicrobial Peptides
• Bacterial Antimicrobial Peptides
• Animal Antimicrobial Peptides
• Insect Antimicrobial Peptides

Ailments

• Pneumonia
• Hepatitis
• Bacterial infections
• HIV

 Distribution Channel

• Hospital
• Research Institutes
• Specialty Clinic
• Pharmacies

Route of Administration

• Topical
• Subcutaneous
• Intravenous

End-user

• Pharma and Healthcare
• Agriculture Industry
• Biological Engineering

Antimicrobial Peptides Market Regional Analysis/Insights

The antimicrobial peptides market is analysed and market size insights and trends are provided by country, product type, application and end-user as referenced above.

The countries covered in the antimicrobial peptides market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominating the market due to advanced or emerging healthcare settings help in restoring the market and increase the reach to a wider section of patients in need.

Asia-Pacific region is expected to be the fastest-growing market during the forecast period 2022-2029. This growth can be attributed to the growing population, increasing income levels, and expanding healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Antimicrobial Peptides Market Share Analysis

항균 펩타이드 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 항균 펩타이드 시장과 관련된 회사의 초점에만 관련이 있습니다.

항균 펩타이드 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 엘리 릴리 앤드 컴퍼니(미국)
• 파이저 주식회사(미국)
• GSK 그룹 회사(미국)
• 노바티스 AG(스위스)
• 엔바이오틱스 주식회사 (미국)
• 존슨앤존슨 프라이빗 리미티드(미국)
• 머크앤코(미국)
• Alexion Pharmaceuticals, Inc. (미국)
• 멜린타 테라퓨틱스, LLC (미국)
• Vertex Pharmaceuticals Incorporated (미국) 
• 아나스펙(미국)
• AMP 바이오텍(인도)
• 피닉스 바이오테크놀로지 주식회사(캐나다)
• 노바바이오틱스(영국)
• 중국펩타이드회사(중국)
• Ontores Biotechnologies Inc.(중국)

SKU-53202